Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 10
147
Views
1
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey

&
Pages 903-911 | Received 02 Jan 2015, Accepted 26 Feb 2015, Published online: 14 Apr 2015
 

Abstract

1. The disposition etamicastat was evaluated in the Cynomolgus monkey after intravenous and oral administration of [14C]-etamicastat. The pharmacokinetics of etamicastat and its N-acetylated metabolite BIA 5-961 were also evaluated in monkeys and dogs.

2. In the monkey, 7 days after intravenous and oral administration of [14C]-etamicastat, 76.6–91.1% of the etamicastat-related radioactivity had been excreted mainly in urine. The radioactivity peaked in plasma between 4- and 8-h post-dosing followed by a quick decline and a slow terminal phase (half-life of 68.7 h). The calculated oral bioavailability for etamicastat was 46.1%. Etamicastat was quickly absorbed in monkeys and dogs with a half-life ranging from 5.2 to 9.9 h in monkeys and 6.9 to 11.4 h in dogs over.

3. The N-acetylated metabolite of etamicastat, represented 4–7% of the extent of exposure of etamicastat in the monkey, but was not found detectable in dogs. Gender did not influence etamicastat exposure and the concentration versus time curves fitted a dose-dependent pharmacokinetics in the dog, but not in the monkey.

4. In conclusion, etamicastat is rapidly absorbed and primarily excreted via urine in monkeys. Similarly, to humans, monkeys, unlike dogs, N-acetylate etamicastat and evidence that etamicastat pharmacokinetics is less than dose proportional.

Declaration of interest

A.I.L. and P.S.S. have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and A.I.L. and P.S.S. were employees of BIAL – Portela & Ca, S.A. in the previous 3 years. BIAL – Portela & Ca, S.A. supported this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.